Discovering the CD96 project with Emilie LOUAT

Continuing our series of portraits dedicated to NVDIAG LabCom students, today we highlight Emilie, a Master 2 student in Biology and Health, specializing in Therapeutic Engineering and Bioproduction in Health Biotechnologies at the University of Montpellier.

Since February, Emilie has been conducting her final internship within the lab, where she focuses on developing nanobodies targeting CD96. This protein, found on the surface of certain immune system cells, plays a key role in tumor progression.

The stakes of her research are major: utilizing the small size and unique properties of camelid nano-antibodies to create cutting-edge tools, both for the diagnosis of leukemia and for new therapeutic strategies such as CAR-T cells. On a daily basis, Emilie is fully integrated into our « EV-nAb » technology platform. She actively participates in all stages of the process: from the production of extracellular vesicles (EVs) displaying receptors in their native form to selection by phage display, and the precise characterization of candidates via ELISA, Western Blot, or flow cytometry.

The expertise she is developing on these complex membrane receptors is at the heart of the innovation driven by NVDIAG to transform research into concrete medical solutions.

Training and supporting the next generation of biotechnology researchers is a central mission of our LabCom. Well done, Emilie, for your commitment to this ambitious project!